ClinicalTrials.gg
RecruitingNCT05417516Updated Sep 14, 2026

A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)

A Phase 3 interventional study of Whole Breast Irradiation (WBI) and Partial Breast Irradiation (PBI) in Breast Neoplasm Female, Radiotherapy and Cosmetic Outcome, sponsored by Ontario Clinical Oncology Group (OCOG). Recruiting at 31 sites in 2 countries. Open to female participants aged 50 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Ontario Clinical Oncology Group (OCOG) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
910
Allocation
Randomized
Ages
50 Years to 120 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG) — 2 open to participants now, 4 under way, 2 of them phase 3. Breast Neoplasms · Ontario Clinical Oncology Group (OCOG).

Planned enrollment
6th of 20
910 · median 318
Started
2023
the only one that year
Phase 3
5 of 24
1 open now
Registered
23rd of 24
by date

Among the 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG), this one is the 6th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2023, is one of 5 in phase 3, and was the 23rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG) are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 50 Years to 120 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG), or all of them as a file.
02

Study summary

The primary objective of this study is to determine in women with node negative BC ≤3cm in size, if PBI compared to WBI, both given once-a-day over 1 week following BCS, is non-inferior for LR and reduces adverse cosmesis. The primary outcomes are LR and patient-assessed cosmesis at 3 years post randomization.

Read the detailed description

This is a randomized, two-arm, single blinded trial comparing two radiation treatment modalities, PBI and WBI. Following BCS or on the completion of additional adjuvant chemotherapy, eligible and consenting patients with newly diagnosed and histologically confirmed invasive carcinoma of the breast (without evidence of metastatic disease); with microscopically clear resection margins of 1mm (or no residual disease on re-excision) and negative axillary node involvement will be randomized in a 1:1 fashion to receive either PBI (experimental group) or WBI (control group). Study participants will receive 26Gy in 5 fractions in both treatment arms, treated once per day, for a period of 5-7 days. Study participants will not be made aware of treatment allocation to prevent any potential bias in their assessment of cosmesis. Stratification factors include tumour size, estrogen receptor (ER) status, and clinical centre.

03

Conditions studied

  • Breast Neoplasm Female
  • Radiotherapy
  • Cosmetic Outcome

Browse trials for

04

Who can participate

Ages eligible
50 Years to 120 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For inclusion in this study, patients must fulfill all of the following criteria:

  1. Female with a new histological diagnosis of invasive carcinoma of the breast with no evidence of disease (see AJCC TNM Cancer Staging, Appendix II).
  2. Treated by BCS with microscopically clear resection margins >= 1mm for invasive and non-invasive disease or no residual disease on re-excision.
  3. Negative axillary node involvement as determined by either sentinel lymph node or axillary node dissection or clinical assessment with a negative axillary ultrasound and/or biopsy, for women with unifocal tumours \<= 2cm, histologic grade 1 or 2, ER or PR+ and -ve that are being planned for endocrine therapy

Exclusion criteria

Exclusion Criteria:

Patients who satisfy any of the following exclusion criteria are NOT eligible for this study:

  1. Age less than 50 years.
  2. Known to be BRCA 1 and/or BRCA 2 positive.
  3. Tumour size >3cm in greatest diameter on pathological examination.
  4. Evidence of extensive intraductal component (EIC) (defined as an invasive tumour with a ductal carcinoma in situ (DCIS) component comprising at least 25% and extending beyond the invasive component to surrounding normal breast tissue) with the following exception: smaller tumours with EIC where the combined size (of the invasive and DCIS components) are \<= 3cm remain eligible
  5. Evidence of a DCIS component > 3cm
  6. Lobular carcinoma only.
  7. More than one primary tumour in different quadrants of the same breast (patients with multifocal breast cancer are eligible).
  8. Synchronous or previous contralateral breast cancer (patients with contralateral DCIS or LCIS are eligible).
  9. History of non-breast within the last 5 years other than treated non-melanoma skin cancer or treated in-situ carcinoma.
  10. Known pregnancy or currently lactating.
  11. Inability to localize tumour bed on CT planning (no evidence of surgical clips or seroma).
  12. Inability to plan the patient for the experimental technique.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
910 participants (estimated)

Study arms

  • Active comparator
    Whole Breast Irradiation (WBI)

    26 Gy in 5 fractions to the whole breast

    Radiation: Whole Breast Irradiation (WBI)

  • Experimental
    Partial Breast Irradiation (PBI)

    26 Gy in 5 fractions to the tumour bed with a margin of normal tissue

    Radiation: Partial Breast Irradiation (PBI)

Interventions

  • RadiationWhole Breast Irradiation (WBI)

    The dose fractionation and prescription is 26Gy in 5 fractions to the PTV once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).

  • RadiationPartial Breast Irradiation (PBI)

    The dose fractionation and prescription is 26Gy in 5 fractions to the PTV prescribed at the isocentre of the treatment fields treated once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).

06

What researchers measure

Primary outcomes

  1. Local Recurrence

    Time from randomization to any evidence of tumour recurrence (invasive and non-invasive) in the treated breast.

    Time frame: Annually for 5 years post-randomization

  2. Patient Assessment Cosmesis at 3 years

    Cosmesis will be assessed by the patient using the Breast Cosmesis Questionnaire which incorporates the Modified EORTC Breast Cosmetic Rating System and the UK Patient Reported Outcomes Questions following BCS.

    Time frame: 3 and 5 years post-randomization

Secondary outcomes

  1. Distant Disease Free Survival (DDSF)

    Time from randomization to evidence of metastasis involving distant sites (e.g. bone, liver, lung, or brain).

    Time frame: Annually for 5 years post-randomization.

  2. Disease Free Survival (DFS)

    Time from randomization to local recurrence, regional or distant recurrence, contralateral breast cancer, other second cancer, or death.

    Time frame: Annually for 5 years post-randomization.

  3. Overall Survival

    Time from randomization to death of any cause.

    Time frame: 3 years post-randomizaton.

  4. Radiation Toxicity

    Acute (2 weeks and up to 3 months after completing RT) and late toxicity (beyond the 3 months after completing RT) will be assessed by clinical centre personnel using the NCI CTCAE version 5.0.

    Time frame: 2 weeks and 3 months post-radiation treatment, then annually for 5 years post-randomization.

  5. Nurse/Clinical Research Associate assessed cosmesis at 3 and 5 years.

    A nurse/Clinical Research Associate (CRA) assessment of cosmesis using the EORTC Breast Cosmetic Rating System. Nurses and CRAs will be training in assessing cosmesis using training slides and guide previously developed for other trials.

    Time frame: 3 and 5 years post-randomization.

  6. Patient Assessed Cosmesis at 5 years.

    Cosmesis will be assessed by the patient using the Breast Cosmesis Questionnaire which incorporates the Modified EORTC Breast Cosmetic Rating System13,27,42 and the UK Patient Reported Outcomes Questions following BCS.

    Time frame: 5 years post-randomization.

  7. Patient Reported Quality of Life

    Patients will complete the EORTC Breast Cancer Quality of life questionnaire

    Time frame: 2 weeks post-radiation treatment, then at 3 and 5 years post-randomization.

07

Study locations

30 of 31 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2029, 72 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 72 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2022
First posted
Jun 14, 2022
StartActual
Nov 20, 2023
Primary completionEst.
Nov 2029
CompletionEst.
Nov 2031
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05417516
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Sponsor
First posted
Jun 14, 2022
Start date
Nov 20, 2023
Primary completion
Nov 2029 (estimated)
Completion
Nov 2031 (estimated)
Last update
Sep 14, 2026

Study contacts

Shelley Chambers, MA
Contact
schamber@mcmaster.ca
905-527-2299 ext. 42618
Erin McGean
Contact
mcgeane@mcmaster.ca
905-527-2299 ext. 42656
Timothy Whelan, M.D.
principal investigator · Juravinski Cancer Centre and McMaster University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion